Comparison of Ocrevus Zunovo Timing in Adults with Relapsing Multiple Sclerosis
This observational study intends to compare the effects of starting Ocrevus Zunovo treatment immediately after a relapse versus delaying treatment in adults with relapsing multiple sclerosis over 18 months. The primary focus is on measuring the annualized relapse rate, which is the number of relapses adjusted to a yearly basis.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
Understanding the timing of treatment initiation could provide insights into better management of relapsing multiple sclerosis, potentially influencing future treatment protocols.
What this does not prove
No results are available yet, and planned enrollment and endpoints of the study represent intentions rather than actual findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 45 · basis not reported
- Randomised
- No
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (11)
limitationsPlanned enrolment and endpoints are not findings.
study designThis prospective, open-label, controlled study will compare rapid initiation of Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with delayed initiation in adults with relapsing multiple sclerosis (MS).
subjectsApproximately 35 adults with relapsing MS will be enrolled at two sites.
sample sizeApproximately 35 adults with relapsing MS will be enrolled at two sites.
randomizedThis is an open-label study; participants and investigators will know which group each participant is in.
controlled"detailedDescription": "This prospective, open-label, controlled study will compare rapid initiation of Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with delayed initiation in adults with relapsing multiple sclerosis (MS).
interventionOcrevus Zunovo is given as an injection under the skin.
comparatorThe other group will start treatment later.
primary endpointAnnualized relapse rate is the number of confirmed multiple sclerosis relapses per participant, adjusted to a one-year period.
follow upParticipants will have blood draws and follow-up visits for up to 18 months.
findingsThis study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.